Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.

Autor: Thompson AJ; Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.; Immunology Research Centre, Department of Medicine (St Vincent's Hospital), The University of Melbourne, Melbourne, Victoria, Australia., Jackson K; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Bonanzinga S; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Hall SAL; Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.; Immunology Research Centre, Department of Medicine (St Vincent's Hospital), The University of Melbourne, Melbourne, Victoria, Australia., Hume S; Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.; Immunology Research Centre, Department of Medicine (St Vincent's Hospital), The University of Melbourne, Melbourne, Victoria, Australia., Burns GS; Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.; Immunology Research Centre, Department of Medicine (St Vincent's Hospital), The University of Melbourne, Melbourne, Victoria, Australia., Sundararajan V; Immunology Research Centre, Department of Medicine (St Vincent's Hospital), The University of Melbourne, Melbourne, Victoria, Australia.; Department of Public Health, La Trobe University, Melbourne, Victoria, Australia., Ratnam D; Gastroenterology & Hepatology Unit, Monash Health, Melbourne, Victoria, Australia.; Monash University, Melbourne, Victoria, Australia., Levy MT; Department of Gastroenterology and Hepatology, Liverpool Hospital, Sydney, Australia., Lubel J; Department of Gastroenterology, Alfred Health, Melbourne, Victoria, Australia.; Central Clinical School, Monash University, The Alfred Centre, Melbourne, Victoria, Australia., Nicoll AJ; Gastroenterology Department of Eastern Health, Melbourne, Victoria, Australia., Strasser SI; AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Sydney, Australia.; University of Sydney, Sydney, Australia., Sievert W; Gastroenterology & Hepatology Unit, Monash Health, Melbourne, Victoria, Australia.; Monash University, Melbourne, Victoria, Australia., Desmond PV; Department of Gastroenterology, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia., Ngu MC; Department of Gastroenterology, Concord Repatriation General Hospital, Sydney, Australia., Sinclair M; Department of Gastroenterology and Hepatology, Austin Health, Melbourne, Victoria, Australia., Meredith C; Department of Gastroenterology, Bankstown-Lidcombe Hospital, Sydney, Australia., Matthews G; Department of Infectious Disease, St Vincent's Hospital Sydney, Sydney, Australia., Revill PA; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Littlejohn M; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Bowden DS; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Canchola JA; Roche Molecular Systems, Inc., Pleasanton, California, USA., Torres J; Roche Molecular Systems, Inc., Pleasanton, California, USA., Siew P; Roche Diagnostics, Pty Ltd, North Ryde, Australia., Lau J; Roche Molecular Systems, Inc., Pleasanton, California, USA., La Brot B; Roche Molecular Systems, Inc., Pleasanton, California, USA., Kuchta A; Roche Molecular Systems, Inc., Pleasanton, California, USA., Visvanathan K; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.

Publikováno v: Hepatology communications [Hepatol Commun] 2023 Jul 17; Vol. 7 (8). Date of Electronic Publication: 2023 Jul 17 (Print Publication: 2023).

The Inaugural Australian Centre for Hepatitis Virology Public Panel Discussion on Viral Hepatitis Research-Lessons in Scientific Community Outreach.

Autor: Tu T; Australian Centre for Hepatitis Virology, Melbourne, VIC 3000, Australia.; Centre for Infectious Diseases and Microbiology, Marie Bashir Institute for Infectious Diseases and Biosecurity, University of Sydney at Westmead Hospital, Westmead, NSW 2145, Australia.; Storr Liver Centre, Westmead Clinical School and Westmead Institute for Medical Research, Faculty of Medicine and Health, The University of Sydney, Westmead, NSW 2145, Australia., Rodrigo C; Australian Centre for Hepatitis Virology, Melbourne, VIC 3000, Australia.; Kirby Institute, UNSW Sydney, Randwick, NSW 2052, Australia.; Department of Pathology, School of Medical Sciences, UNSW Sydney, Sydney, NSW 2052, Australia., Strasser SI; AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.; Sydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia., Bowden DS; Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia., MacLachlan JH; WHO Collaborating Centre for Viral Hepatitis, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.; Department of Medicine, University of Melbourne, Parkville, VIC 3010, Australia., Drummer HE; Viral Entry and Vaccines Group, Burnet Institute, Melbourne, VIC 3004, Australia.; Department of Microbiology and Immunology, Peter Doherty Institute for Infection and Immunity, University of Melbourne, Melbourne, VIC 3000, Australia.; Department of Microbiology, Monash University, Clayton, VIC 3800, Australia.

Publikováno v: Viruses [Viruses] 2021 Sep 15; Vol. 13 (9). Date of Electronic Publication: 2021 Sep 15.

ELISA genotyping of hepatitis B virus in China with antibodies specific for genotypes B and C.

Autor: Li, Yumin¹ (AUTHOR), Wang, Li¹ (AUTHOR), Cheng, Huanyi² (AUTHOR), Chi, Xiumei³ (AUTHOR), Huang, Qingrui² (AUTHOR), Lv, Pinxin⁴ (AUTHOR), Zhang, Wenyi² (AUTHOR), Niu, Junqi⁵ (AUTHOR), Wen, Xiaoyu⁵ (AUTHOR) xywen@jlu.edu.cn, Liu, Zhenning¹ (AUTHOR) liu_zhenning@jlu.edu.cn

Publikováno v: Scientific Reports. 10/12/2024, Vol. 14 Issue 1, p1-15. 15p.

Localization of rubella virus core particles in vero cells

Autor: Marshall Ja, J.Y. Lee, Bowden Ds

Publikováno v: Virology. 265(1)

Rubella virus (RV) infection induces a variety of morphological changes in the host cell including the modification of lysosomes to produce “replication complexes” and the alteration of mitochondrial morphology and distribution. The morphogenesis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::798cfc194543d0fb763a00396d85790a
https://pubmed.ncbi.nlm.nih.gov/10603322

Hepatitis C virus genotypes in Australia

Autor: Bowden Ds, Stephen Locarnini, Moaven Ld, R. McCaw

Publikováno v: Journal of viral hepatitis. 4(5)

The relative distribution of Australian hepatitis C virus (HCV) genotypes was determined for 500 isolates. Genotyping was performed using a commercial reverse phase hybridization assay after amplification of the 5' untranslated region of HCV by the p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8a1d4fb283a39e95ad136318ab5e32a
https://pubmed.ncbi.nlm.nih.gov/9310934